May 24, 2024

apomares/E+ by way of Getty Pictures

Introduction & Thesis

Shares of biopharma Lexicon Prescribed drugs, Inc. (NASDAQ:LXRX) are ~60% off their Might highs, regardless of holding an FDA-approved key drug (Inpefa) for coronary heart failure in its portfolio. The sell-off is essentially attributed to investor issues over Inpefa’s market